Advertisement

Opioids and Antagonists

  • Sergio Canavero
  • Vincenzo Bonicalzi
Chapter

Abstract

Opioids (including tramadol and, pending confirmation, cebranopadol) are not indicated in the routine management of CP, alone or in combination (e.g., with aminergics) [1, 2]. The first patient in history to be diagnosed with CP was also opioid unresponsive [3]. Most chronic pain patients on long-term opioids report strong or very strong pain, highlighting their inefficacy [4, 5]. In short-term clinical trials of PNP, the NNT for strong opioids was 4.3 and for tramadol 4.7.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Canavero S, Bonicalzi V. The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications. Pain. 1998;74(2-3):109–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Canavero S, Bonicalzi V. Chronic neuropathic pain. N Engl J Med. 2003;348(26):2688–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Edinger L. Giebt es central entstehende Schmerzen? Dtsch Z Nervenheilk. 1891;1:262–82.CrossRefGoogle Scholar
  4. 4.
    Fredheim OM, Mahic M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population-based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Trøndelag health study. Pain. 2014;155(7):1213–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Moulin DE, Clark AJ, Gordon A, Lynch M, Morley-Forster PK, Nathan H, Smyth C, Toth C, Van Den Kerkhof E, Gilani A, Ware MA. Long-term outcome of the management of chronic neuropathic pain: a prospective observational study. J Pain. 2015;16(9):852–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008;35:214–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Demarest SP, Gill RS, Adler RA. Opioid endocrinopathy. Endocr Pract. 2015;21(2):190–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Carbone LD, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, Akhigbe T, Weaver FM. The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med. 2013;36(2):91–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Valverde-Filho J, da Cunha Neto MB, Fonoff ET, Meirelles Ede S, Teixeira MJ. Chronic spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain patients. Pain Med. 2015;16(4):715–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly S, Trivelas N, Kirsling A, Harden RN. Opioids do not improve function. Pain Med. 2015;16(A173):590–1.Google Scholar
  11. 11.
    Ekholm O, Kurita GP, Højsted J, Juel K, Sjøgren P. Chronic pain, opioid prescriptions, and mortality in Denmark: a population-based cohort study. Pain. 2014;155(12):2486–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Hooten WM, Lamer TJ, Twyner C. Opioid-induced hyperalgesia in community-dwelling adults with chronic pain. Pain. 2015;156(6):1145–52.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Woller SA, Hook MA. Opioid administration following spinal cord injury: implications for pain and locomotor recovery. Exp Neurol. 2013;247:328–41.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pedersen L, Fredheim O. Opioids for chronic noncancer pain: still no evidence for superiority of sustained-release opioids. Clin Pharmacol Ther. 2015;97(2):114–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Arnér S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33(1):11–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain. 1991;47(1):5–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology. 2002;58(4):554–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Kalman S, Osterberg A, Sörensen J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6(1):69–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet. 1997;349(9054):753–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery. 1995;37(6):1080–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990;43(3):273–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 1990;240(1):1–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336(7637):199–201.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17(7):576–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial. Clin J Pain. 2009;25(3):177–84.CrossRefPubMedGoogle Scholar
  27. 27.
    Bainton T, Fox M, Bowsher D, Wells C. A double-blind trial of naloxone in central post-stroke pain. Pain. 1992;48(2):159–62.CrossRefPubMedGoogle Scholar
  28. 28.
    Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–50.PubMedGoogle Scholar
  29. 29.
    Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(8):964–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Barrera-Chacon JM, Mendez-Suarez JL, Jáuregui-Abrisqueta ML, Palazon R, Barbara-Bataller E, García-Obrero I. Oxycodone improves pain control and quality of life in anticonvulsant-pretreated spinal cord-injured patients with neuropathic pain. Spinal Cord. 2011;49(1):36–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Guetti C, Angeletti C, Marinangeli F, Ciccozzi A, Baldascino G, Paladini A, Varrassi G. Transdermal buprenorphine for central neuropathic pain: clinical reports. Pain Pract. 2011;11(5):446–52.CrossRefPubMedGoogle Scholar
  32. 32.
    Weiner M, Sarantopoulos C, Gordon E. Transdermal buprenorphine controls central neuropathic pain. J Opioid Manag. 2012;8(6):414–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Tanei T, Kajita Y, Noda H, Takebayashi S, Hirano M, Nakahara N, Wakabayashi T. [Efficacy of tramadol/acetaminophen medication for central post-stroke pain]. No Shinkei Geka. 2013;41(8):679–85.Google Scholar
  34. 34.
    Madeo G, Schirinzi T, Natoli S, Pierantozzi M, Stefani A, Dauri M, Pisani A. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain. J Neurol. 2015;262(9):2164–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Yamamoto T, Watanabe M, Obuchi T, Kano T, Kobayashi K, Oshima H, Fukaya C, Yoshino A. Importance of pharmacological evaluation in the treatment of poststroke pain by spinal cord stimulation. Neuromodulation. 2016;19(7):744–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Gear R, Becerra L, Upadhyay J, Bishop J, Wallin D, Pendse G, Levine J, Borsook D. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. PLoS One. 2013;8(1):e50169.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Baumgärtner U, Buchholz HG, Bellosevich A, Magerl W, Siessmeier T, Rolke R, Höhnemann S, Piel M, Rösch F, Wester HJ, Henriksen G, Stoeter P, Bartenstein P, Treede RD, Schreckenberger M. High opiate receptor binding potential in the human lateral pain system. Neuroimage. 2006;30:692–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sergio Canavero
    • 1
  • Vincenzo Bonicalzi
    • 2
  1. 1.HEAVEN/GEMINI International Collaborative GroupTurinItaly
  2. 2.AOUCittà della Salute e della Scienza di Torino, Department of Neurosciences, Rita Levi MontalciniUniversità di TorinoTurinItaly

Personalised recommendations